Sophie Opdyke is responsible for building the U.S. Oncology division, leading its day-to-day operations, and shaping its long-term strategic business plan. This includes leading the potential commercial launch of an investigational gene therapy for high-grade, non-muscle invasive bladder cancer patients, who are unresponsive to BCG therapy.
Sophie joined Ferring in January, 2019. She has more than 20 years of experience in the pharmaceutical industry. Most recently at Pfizer, she led the development and execution of Pfizer’s strategy in Immuno-Oncology. Specifically, she oversaw all associated commercial activities from pre-clinical through launch for the company’s portfolio, including check point inhibitors, novel Immuno-Oncology targets and innovative technologies such as allogenic CAR-T and immune therapy-based vaccines. During her tenure, Opdyke was also instrumental in building and leading Pfizer’s Global Biosimilars organization, driving a core component of its biotherapeutics strategy.
Sophie holds a doctorate of Pharmacy and Master of Pharmaceutical Business from Université Paris Descartes and an MBA in finance and international business from Columbia Business School.